swatsurgeon
11-13-2008, 20:35
Primaquine Linked to Risk for Hemolytic Anemia in Certain Patients
On July 28, the FDA approved class safety labeling revisions for primaquine phosphate tablets (sanofi-aventis US) to warn that treatment should be discontinued in patients with signs suggestive of hemolytic anemia, such as darkened urine and a marked decrease in hemoglobin or erythrocyte count.
According to the FDA, moderate to severe hemolytic reactions may occur in individuals with glucose-6-phosphate dehydrogenase deficiency and in those with a family or personal history of favism.
Patients from areas with a high prevalence of glucose-6-phosphate dehydrogenase deficiency (Africa, Southern Europe, the Mediterranean region, Middle East, South-East Asia, and Oceania) may be at increased risk for the development of hemolytic anemia while receiving primaquine and related drugs.
Primaquine is indicated for the radical cure (prevention of relapse) of vivax malaria.
Just thought people should be aware of this...is this still a prophylaxis of choice?
ss
On July 28, the FDA approved class safety labeling revisions for primaquine phosphate tablets (sanofi-aventis US) to warn that treatment should be discontinued in patients with signs suggestive of hemolytic anemia, such as darkened urine and a marked decrease in hemoglobin or erythrocyte count.
According to the FDA, moderate to severe hemolytic reactions may occur in individuals with glucose-6-phosphate dehydrogenase deficiency and in those with a family or personal history of favism.
Patients from areas with a high prevalence of glucose-6-phosphate dehydrogenase deficiency (Africa, Southern Europe, the Mediterranean region, Middle East, South-East Asia, and Oceania) may be at increased risk for the development of hemolytic anemia while receiving primaquine and related drugs.
Primaquine is indicated for the radical cure (prevention of relapse) of vivax malaria.
Just thought people should be aware of this...is this still a prophylaxis of choice?
ss